Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
The FDA’s Circulatory System Devices Panel narrowly approved an expanded indication for all of Medtronic’s cardiac resynchronization therapy pacemakers and cardiac resynchronization therapy defibrillators.
Amaranth Medical raises $20 million in a Series B financing round to help the company chase European regulatory approval for its Fortitude bioresorbable scaffold.
Johnson & Johnson’s DePuy Synthes subsidiary goes after a trio of ex-sales reps now working for rival Globus Medical in Texas.